Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of Gene Therapy for Parkinson's disease (AAV-hAADC-2)
jRCT2033210696Phase 2Completed
- Sponsor
- Gene Therapy Research Institute
- Start
- Sep 2022
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ezaladcigene resoparvovec in Parkinson's disease (PD), sponsored by Gene Therapy Research Institute. Primary endpoint: Primary safety and efficacy. Started Sep 2022; status: completed.
02
Drugs
ezaladcigene resoparvovec
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2033210696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033210696.